Immune checkpoint therapy is being tested in the neoadjuvant setting for patients with
localized urothelial carcinoma,, with one study reporting data in cisplatin-ineligible patients …

Preoperative immunotherapy with anti-PD1 plus anti-CTLA4 antibodies has shown
remarkable pathological responses in melanoma and colorectal cancer. In NABUCCO …

Antibodies targeting PD-1 or its ligand 1 PD-L1 such as atezolizumab, have great efficacy in
a proportion of metastatic urothelial cancers,. Biomarkers may facilitate identification of these …

Abstract Purpose of Review Until recently, effective treatment options for patients with
advanced urothelial carcinoma were limited to platinum-based chemotherapy. In the post …

5047 Background: Patients (pts) with laUC who are C-eligible for N-therapy may benefit from
combination chemo-immunotherapy. Cohort 1 (C1) of the GU14-188 trial is a phase 1b/2 …

Cohort 1 of the phase 1B NABUCCO trial showed high pathological complete response
(pCR) rates with preoperative ipilimumab plus nivolumab in stage III urothelial cancer (UC) …

Background Patients with metastatic urothelial carcinoma have a dismal prognosis and few
treatment options after first-line chemotherapy. Responses to second-line treatment are …

Background While immune checkpoint inhibitors (ICIs) are approved in the first-line (1L)
setting for cisplatin-unfit patients with programmed death-ligand 1 (PD-L1)-high tumors or for …

Background Limited data compare first-line carboplatin-based chemotherapy and immune
checkpoint blockade in cisplatin-ineligible metastatic urothelial carcinoma (mUC) patients …

Background No new agent has improved overall survival in patients with unresectable or
metastatic urothelial carcinoma when added to first-line cisplatin-based chemotherapy …